Onesource Specialty Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Onesource Specialty Pharma share price target stands at Rs 1,930 for 2026, implying approximately 17% upside from the current market price of Rs 1,650. The stock trades at a price-to-earnings ratio of 1047.74x, pricing in robust earnings growth expectations, with a market capitalisation of Rs 18,934 Cr. Investors tracking the pharmaceuticals segment are closely watching Onesource Specialty Pharma as an emerging opportunity given its 52-week range of Rs 1,057 to Rs 2,141. This analysis covers the bull case, bear case, and key catalysts that will define the Onesource Specialty Pharma share price target trajectory through 2026.

Click Here – Get Free Investment Predictions

Onesource Specialty Pharma Company Overview and Key Metrics

Onesource Specialty Pharma	Details
NSE Symbol	ONESOURCE
Sector	Pharmaceuticals
CMP (Rs)	1,650
52W High (Rs)	2,141
52W Low (Rs)	1,057
Market Cap (Rs Cr)	18,934 Cr
P/E Ratio	1047.74
12M Target (Rs)	1,930
Bull Case (Rs)	2,220
Bear Case (Rs)	1,485

Onesource Specialty Pharma is a pharmaceuticals company listed on the National Stock Exchange (NSE: ONESOURCE). With a market capitalisation of Rs 18,934 Cr, the company occupies a defined position in the Indian pharmaceuticals landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 2,141 and a low of Rs 1,057, before arriving at its current level of Rs 1,650. Uniresearch analysts project a 12-month Onesource Specialty Pharma share price target of Rs 1,930, with a bull case of Rs 2,220 and a bear case of Rs 1,485.

Why Is the Onesource Specialty Pharma share price target Set at Rs 1,930 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Onesource Specialty Pharma share price target of Rs 1,930 is anchored in expectations of FY27 earnings delivery. At a P/E of 1047.74x on trailing earnings, the stock is priced for consistent execution. Consistent revenue growth and margin improvement in coming quarters can re-rate the stock towards the Rs 1,930 target.

Domestic Formulations Growth and NLEM Coverage

India’s pharma market is expanding at 10-12% annually driven by rising health awareness and increasing prescription volumes. Companies with a strong domestic branded generic presence are well-positioned to capture this structural demand growth.

USFDA and Export Approvals Pipeline

Pharma companies that successfully navigate USFDA inspections and build a credible ANDA pipeline can see significant margin expansion through regulated market sales. Export realizations are typically three to five times domestic pricing.

RBI Rate Cut Cycle and Lower Cost of Capital

The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Onesource Specialty Pharma, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Onesource Specialty Pharma share price target to materialise by year-end.

Union Budget 2026 and Policy Tailwinds

The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including pharmaceuticals. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Onesource Specialty Pharma share price target thesis through improved demand visibility.

Onesource Specialty Pharma Share Price Target Short Term, 12 Month and Long Term

Short Term Onesource Specialty Pharma Share Price Target: 3 to 6 Months

In the near term, the Onesource Specialty Pharma share price target for the next 3 to 6 months is pegged at Rs 1,780, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the pharmaceuticals segment. Technically, the stock needs to hold the Rs 1,110-1,163 zone for this short-term target to remain valid.

12 Month Onesource Specialty Pharma Share Price Target 2026

Our 12-month Onesource Specialty Pharma share price target is Rs 1,930. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 1,930 level represents approximately 17% upside from the current price of Rs 1,650.

Long Term Onesource Specialty Pharma Share Price Target: FY27 to FY28

Over a 2 to 3 year horizon, the long-term Onesource Specialty Pharma share price target is estimated between Rs 2,220 and Rs 2,606, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 1,650 an attractive accumulation level.

Bull Case and Bear Case for Onesource Specialty Pharma Share Price Target

Bull Case: Rs 2,220

In the bull case scenario, Onesource Specialty Pharma delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Onesource Specialty Pharma share price target could reach Rs 2,220, implying approximately 35% upside from the current market price.

Bear Case: Rs 1,485

The bear case of Rs 1,485 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Onesource Specialty Pharma could re-test support levels closer to its 52-week low of Rs 1,057, representing a downside risk investors should monitor.

Scenario	Target Price (Rs)	Upside/Downside from CMP	Key Assumption
Bull Case	2,220	35%	Strong earnings growth, sector re-rating
Base Case	1,930	17%	Steady earnings, margin improvement
Bear Case	1,485	-10%	Earnings miss, macro headwinds

Key Risks to the Onesource Specialty Pharma Share Price Target 2026

Macro Headwind from Global Slowdown and US Tariff Policy

A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Onesource Specialty Pharma faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.

Valuation Risk and Earnings Miss Scenario

If Onesource Specialty Pharma reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.

Competitive Pressure in the Pharmaceuticals Segment

The pharmaceuticals space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Onesource Specialty Pharma’s revenue trajectory.

FII Selling and Broader Market Volatility

Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Onesource Specialty Pharma’s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.

How to Invest in Onesource Specialty Pharma Stock

Step 1: Research and Fundamental Analysis. Before investing, thoroughly review Onesource Specialty Pharma’s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Onesource Specialty Pharma share price target of Rs 1,930 is achievable.

Step 2: Use Stock Screeners for Live Data.

Check Onesource Specialty Pharma Live Data on Univest Screener

Monitor key metrics including P/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Onesource Specialty Pharma share price target thesis in real time.

Step 3: Define Your Entry Zone. The current CMP of Rs 1,650 is within the identified accumulation zone based on the 52-week low of Rs 1,057 and the Uniresearch target of Rs 1,930. Consider entering in tranches to average your cost over market fluctuations.

Step 4: Set Stop Loss and Risk Management Levels. Always define a stop-loss level before investing. A prudent stop-loss for Onesource Specialty Pharma based on the current technical setup would be in the Rs 1,452 to Rs 1,518 range. Never risk more than 2-5% of your portfolio in any single position.

Step 5: Open a Zero-Brokerage Demat Account. To invest in Onesource Specialty Pharma at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Onesource Specialty Pharma share price target analysis without incurring unnecessary transaction costs.

Download the Univest iOS App or Univest Android App to track Onesource Specialty Pharma live price and get daily stock recommendations.

Conclusion

The Onesource Specialty Pharma share price target for 2026 is Rs 1,930, with a bull case of Rs 2,220 and a bear case of Rs 1,485, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 1,650 with a 52-week range of Rs 1,057 to Rs 2,141, Onesource Specialty Pharma presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Onesource Specialty Pharma share price target outlined here is for educational purposes only.

FAQs on Onesource Specialty Pharma Share Price Target 2026

What is the Onesource Specialty Pharma share price target for 2026?

Ans. The Onesource Specialty Pharma share price target for 2026, as per Uniresearch estimate, is Rs 1,930. This implies approximately 17% upside from the current market price of Rs 1,650.

Is Onesource Specialty Pharma a good stock to buy right now?

Ans. Whether Onesource Specialty Pharma is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Onesource Specialty Pharma share price target of Rs 1,930 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.

What is Onesource Specialty Pharma’s 52-week high and low?

Ans. Onesource Specialty Pharma’s 52-week high is Rs 2,141 and the 52-week low is Rs 1,057, as of 29 June 2026. The current price of Rs 1,650 represents a 56% gain from the 52-week low.

What is the market cap of Onesource Specialty Pharma?

Ans. The market capitalisation of Onesource Specialty Pharma is approximately Rs 18,934 Cr, as of 29 June 2026.

What are the key risks to the Onesource Specialty Pharma share price target?

Ans. Key risks to the Onesource Specialty Pharma share price target of Rs 1,930 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the pharmaceuticals sector. Any of these factors could delay or reduce the target realisation.

What is the bull case target for Onesource Specialty Pharma in 2026?

Ans. In the bull case scenario, the Onesource Specialty Pharma share price target could reach Rs 2,220, implying approximately 35% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.

Where can I track Onesource Specialty Pharma share price live?

Ans. You can track Onesource Specialty Pharma (NSE: ONESOURCE) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.

How do I invest in Onesource Specialty Pharma stock?

Ans. To invest in Onesource Specialty Pharma, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker ONESOURCE on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.